A Study of SKB315 in Patients With Advanced Solid Tumors

  • STATUS
    Recruiting
  • End date
    May 31, 2024
  • participants needed
    206
  • sponsor
    Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Updated on 26 May 2022

Summary

This is a multicenter, open-label, multiple-dose dose finding and expansion study to evaluate the safety, tolerability, pharmacokinetic(PK) profile, and anti-tumor efficacy of SKB315 for injection in patients with advanced solid tumors.

Description

This is a multicenter, open-label, multiple-dose dose finding and expansion study to evaluate the safety, tolerability, PK profile, and anti-tumor efficacy of SKB315 for injection in patients with advanced solid tumors.The study is divided into Phase 1a and Phase 1b: Phase 1a is a dose escalation study to determine the maximum tolerated dose(MTD); Phase 1b is a dose expansion study to conduct preliminary evaluation of anti-tumor efficacy and further evaluation of safety, tolerability, PK, and immunogenicity of SKB315.

Details
Condition Advanced Solid Tumors
Treatment SKB315 for injection
Clinical Study IdentifierNCT05367635
SponsorSichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Last Modified on26 May 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Male or female patients aged 18 to 80 years (inclusive) at the time of signing the informed consent form (ICF)
Patients with histologically and/or cytologically confirmed advanced solid tumors who have failed standard of care, or who have no available standard of care regimen, or who are unqualified for standard of care
Consent to provide archival or fresh tumor tissue slides for immunohistochemistry (IHC) assessment, and advanced solid tumors with Claudin 18.2 expression as determined by IHC
Presence of at least one measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
Estimated survival ≥ 3 months as judged by the investigator
Adequate organ and bone marrow function (no blood components and cytokines are allowed within 2 weeks prior to the first dose)
Have recovered to ≤ Grade 1 (according to national cancer institute (NCI) common terminology criteria adverse events (CTCAE) V5.0) from previously treated toxicity prior to the first dose of study treatment
Patients of childbearing potential (male or female) must use effective medical contraception during the study and for 6 months after the end of dosing
Patients voluntarily participate in the study, sign the ICF, and will be able to comply with the protocol-specified visits and relevant procedures

Exclusion Criteria

Received other drugs in clinical study, major surgeries, or any other anti-tumor therapies within 4 weeks prior to the first dose of study treatment
Received any previous therapy targeting Claudin18.2
Plan to receive any other anti-tumor therapy during the study
Received strong cytochrome P450 3A4(CYP3A4) inhibitors or inducers within 2 weeks prior to the first dose of study treatment or within 5 half-lives of drug elimination, whichever is longer
Have other malignancies within 5 years prior to signing of ICF
Pregnant or lactating women
Known history of allergy to any component of SKB315 or other monoclonal antibodies (mAbs)
Known history of alcohol abuse (consumption of more than 14 units of alcohol per week or drug abuse)
Patients with active hepatitis B or hepatitis C
Human immunodeficiency virus (HIV) positive
Active severe digestive disease
History of major cardiovascular diseases
Confirmed serious lung disease or lung disease that may impair the respiratory reserve function of the patient as judged by the investigator
History of serious dementia, altered mental status, or any psychiatric disorder
Concomitant or known metastases to brain or central nervous system
Have clinically significant systemic diseases that may adversely affect the safety of the study
Subjects who may have poor compliance with the clinical study or have other factors based on which the investigator considers that the subjects are not appropriate to participate in the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note